Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 8/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951844 | 1.00 | CHRM3 (0.49) | CHRM3DPP4DPP7CCR5CNR1 | |
| SCHEMBL3955347 | 0.99 | CHRM3 (0.48) | CHRM3DPP4DPP7CCR5SLC6A3 | |
| SCHEMBL4565133 | 0.84 | CHRM3 (0.45) | CHRM3CCR5 | |
| SCHEMBL3952009 | 0.84 | DPP4 (0.43) | DPP4DPP7CCR5LMNATSHR | |
| SCHEMBL3960353 | 0.83 | SLC6A2 (0.44) | DPP4DPP7SLC6A3LMNATSHR | |
| SCHEMBL27662441 | 0.81 | CHRM3 (0.49) | CHRM3CCR5LMNATSHRMAPK1 | |
| SCHEMBL27662364 | 0.81 | CHRM3 (0.60) | CHRM3CNR1CNR2LMNATSHR | |
| SCHEMBL27681954 | 0.80 | CHRM3 (0.50) | CHRM3CCR5LMNATSHRMAPK1 | |
| SCHEMBL27662329 | 0.79 | CHRM3 (0.59) | CHRM3CNR1CNR2LMNATSHR | |
| SCHEMBL3954438 | 0.79 | LMNA (0.40) | DPP4DPP7CCR5LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | CHRM3 481/4885DPP4 375/4885DPP7 462/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | CHRM3 1108/4885DPP4 1454/4885DPP7 2569/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | CHRM3 853/4885DPP4 599/4885DPP7 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.